Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study-Reference-Cited by-同舟云学术

Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study

Published:2006 Issue:9 Volume:54 Page:2807-2816
ISSN:0004-3591
Container-title:Arthritis & Rheumatism
language:en
Short-container-title:Arthritis Rheum

Author:

Weinblatt M.,Combe B.,Covucci A.,Aranda R.,Becker J. C.,Keystone E.

Publisher

Wiley

Subject

Pharmacology (medical),Immunology,Rheumatology,Immunology and Allergy

Reference13 articles.

1. Cytokine Pathways and Joint Inflammation in Rheumatoid Arthritis

2. The Role of Novel T Cell Costimulatory Pathways in Autoimmunity and Transplantation

3. CTLA-4 -- The Costimulatory Molecule That Doesn't: Regulation of T-cell Responses by Inhibition

4. Treatment of Rheumatoid Arthritis by Selective Inhibition of T-Cell Activation with Fusion Protein CTLA4Ig

5. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial

Cited by 330 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sicca syndrome/Sjögren’s disease associated with cancer immunotherapy: a narrative review on clinical presentation, biomarkers, and management;Expert Review of Clinical Immunology;2024-06-25

2. Infection outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: Results from a 10-year international post-marketing study;Seminars in Arthritis and Rheumatism;2024-02

3. Malignancy outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: Results from a 10-year international post-marketing study;Seminars in Arthritis and Rheumatism;2024-02

4. Lymphocytes and Infection in Autoimmune Diseases;Infection and Autoimmunity;2024

5. Immune-mediated inflammatory diseases: Common and different pathogenic and clinical features;Autoimmunity Reviews;2023-10